Correspondence
Contact Shop TB-500.
For editorial questions and corrections to our reading of the TB-500 literature. We do not sell, prescribe, or advise.
Editorial correspondence only
This is an editorial publisher covering the TB-500 and thymosin beta-4 research record. Use the form below for editorial matters: a question about how we read a study, a correction to a citation, or a pointer to a paper we should add. We read every message in that spirit.
What this channel is not: it is not a clinical service, a pharmacy, or a sales desk. We cannot provide medical advice, recommend doses, evaluate anyone for treatment, or help anyone obtain any substance. We sell nothing and we hold no products. Questions about purchasing, prescriptions, or personal use fall outside what an editorial project can answer, and we will not respond to them with anything beyond this note.
Send a note
Use the contact form to reach the editorial desk. A name, an email address, and your message are enough. For corrections, a link or a citation helps us verify quickly; for additions, the DOI or PubMed identifier of the study lets us slot it into the study references and citations register without ambiguity. We aim to read correspondence promptly, though this is a small editorial project and not a staffed service line.
If your question is about purchasing, prescriptions, dosing, or personal use, this is the wrong desk and we cannot help — those fall outside what an editorial publisher does, and the TB-500 legal status and 503A access page already lays out, in general terms, how legally compounded peptide access works under the FDA's framework. We will not provide vendor names, protocols, or any guidance on obtaining TB-500. What we will do is keep the reading of the science accurate, and fix it fast when a reader shows us we have it wrong.